Date:
4/24/17
End Date:
2/12/19
First in-human trial results of nanoformulations of efavirenz and lopinavir confirmed the potential for a 50% dose reduction to the current standard oral dose of both antiretrovirals.
Andrew Owen presented these findings at CROI 2017 on behalf of colleagues from the University of Liverpool, St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, Clinton Health Access Initiative, Boston, and the Medicines Patent Pool, Geneva.